Blastocyst IVF Screening Boosts Safety & Pregnancy Success

New research published in _Fertility & Sterility_ reveals that delaying embryo chromosomal screening until the blastocyst stage (day 5) improves IVF success rates by 30% compared to day 3 testing. RMA Genetics now exclusively uses this method, which removes cells only from the placenta-forming trophectoderm layer, preserving fetal cell integrity. SelectCCS technology now screens all 24 chromosomes to identify viable embryos for transfer.

---

Key Takeaways

Blastocyst Stage Biopsy Safely Identifies Chromosomally Normal Embryos

Testing at day 5 when embryos have 200+ cells allows safe extraction of trophectoderm cells (future placenta) without damaging fetal cell lines. This method reduces implantation failure risks by 40% compared to day 3 testing which removes 16.7% of the embryo’s total volume.

Day 3 Cleavage-Stage Biopsy Risks Embryo Implantation Failure

Traditional day 3 testing on 6-8 cell embryos compromises development by removing critical cells. Studies show 35% of day 3 biopsied embryos fail to implant successfully, compared to 9% failure rate with blastocyst-stage biopsies.

SelectCCS 24-Chromosome Screening Ensures Euploid Embryo Selection

RMA’s proprietary SelectCCS platform detects euploid embryos with 99.9% accuracy by analyzing all 24 chromosomes. This prevents aneuploidy-related miscarriages that account for 50% of early pregnancy failures.

Single Embryo Transfer (SET) Reduces Twin Pregnancy Complications

Combining blastocyst screening with SET achieves 78% live birth rates while eliminating 34% of IVF complications associated with multiple gestations. This approach reduces preterm birth rates from 54% to 12%.

Time-Lapse Imaging Doesn’t Replace Chromosome Screening Accuracy

Despite visual embryo quality assessments, 45% of morphologically perfect day 3 embryos tested aneuploid. Only blastocyst-stage chromosome screening reliably predicts implantation potential.

---

Source: Read full article